EICHORCondition: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal Adenocarcinoma · Sponsor: Jazz Pharmaceuticals
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Hospital de Gastroenterología Dr Bonorino Udaondo | Buenos Aires, Argentina | — |
| Instituto de Investigaciones Metabólicas - IDIM | Buenos Aires, Argentina | — |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | — |
| Fundación Centro de Medicina Nuclear y Molecular ER | Córdoba, Argentina | — |
| Centro Médico Privado CEMAIC | Córdoba, Argentina | — |
| Centro de Investigación Pergamino S.A. | Pergamino, Argentina | — |
| Centro de Investigación Clínica - Clínica Viedma | Viedma, Argentina | — |
| Flinders Medical Centre | Bedford Park, Australia | — |
| Austin Health | Heidelberg, Australia | — |
| Liverpool Hospital | Liverpool, Australia | — |
| Fiona Stanley Hospital | Murdoch, Australia | — |
| Imelda VZW | Bonheiden, Belgium | — |
+ 215 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05152147